Mammalian Cell Culture Market Size, Share and Trends Analysis, By Product (Consumables and Equipment), By Application, By End-Use (Pharmaceutical & Biotechnology Companies, Hospitals and Diagnostic Laboratories, Research & Academic Institutes, and Contract Research Organizations (CROs), and By Region, Forecast 2025-2032

Mammalian Cell Culture Market Overview and Key Insights:

The mammalian cell culture market size reached USD 3,348.6 Million in 2024 and is expected to register a revenue CAGR of 12.8% during the forecast period. Mammalian cell culture is the process of growing animal cells outside of their natural tissue, in a growth media instead. Cells are normally cultivated in a cell culture vessel, such as a shaking flask, which is then placed in an incubator to create a controlled environment for optimal growth.

Market Drivers:

Rising prevalence of chronic diseases is a key driver of revenue growth in the mammalian cell culture market. According to the National Cancer Institute (NCI), in 2024, a projected 2 million new instances of cancer will be identified in the United States, with 611,720 deaths from the disease. Prostate, lung, and colorectal cancers will account for an estimated 48% of all malignancies diagnosed in males by 2024. Breast, lung, and colorectal cancers are the three most frequent among women, accounting for an anticipated 51% of all new cancer diagnoses in 2024. As of January 2022, the United States has an estimated 18.1 million cancer survivors. The number of cancer survivors is expected to rise to 22.5 million by 2032.

Rising demand for biologics is a significant driver driving the market growth over the forecasted period. Mammalian cell culture is the most popular way of producing biologics. Mammalian cell culture is widely used in the pharmaceutical industry to generate antibodies and other large protein molecules that require post-translational modifications. On January 2024, WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the release of WuXiaADCC PLUSTM, a high-performing and high-yielding mammalian cell line platform for the development and manufacturing of afucosylated antibodies that elicit an enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) response.

Market Opportunity:

Increasing demand for personalized medicine acts as an opportunity for the mammalian cell culture market. Personalized medicine seeks to deliver individualized medical therapy based on patients’ clinical, genetic, and environmental features. Patient-derived tumor 3D models are proving to be more relevant than typical 2D cell cultures for medication efficacy and toxicity screening. 3D cell culture models can be used to model a variety of diseases, including cancer and genetic abnormalities, because they closely resemble the behavior of human tissues, allowing researchers to investigate diseases in a more realistic setting and develop individualized treatments.

On July 2024, Qkine, a specialist bioactive protein maker, has announced a new cooperation with StemCultures, a life sciences firm focused on developing revolutionary reagents that improve the quality and efficiency of cell growth and differentiation in culture. This cooperation brings together Qkine’s experience in complicated protein synthesis and engineering with StemCultures’ exclusive controlled-release technology to provide new reagents for precise stem cell proliferation and differentiation.

Recent Trends:

Emerging trends include integration with automated and high-throughput systems, 3D cell culture technologies, media advancements, advances in monitoring and control, and integration with regenerative medicine.

Emerging technologies such as automated and high-throughput systems is a significant trend for mammalian cell culture market. Automated cell culture systems are gaining popularity because they offer the potential to overcome the disadvantages of manual cell culture by increasing dependability and scalability, as well as allowing trained workers to be redeployed. Automated systems have the potential to perform significantly more analysis because they can work outside of normal business hours and collect more detailed data. Automation of cell culture applications offers a unique opportunity to layer in the collection of a larger dataset than would be possible using typical manual procedures.

On February 2024, Cell Microsystems, a leading producer of innovative cell biology instruments, announced a strategic agreement with OMNI Life Science (OLS), a well-known German cell biology firm. This alliance seeks to offer three breakthrough products to the US and Canadian markets: the CERO, CASY, and TIGR, which will be a huge step forward in North American life science research.

Restraints & Challenges:

Researchers often use mammalian cells as expression platforms for recombinant protein production because these cells perform post-translational modifications and release properly folded, functional proteins. Mammalian cells are more challenging to work with than bacterial or yeast expression systems because they require more sophisticated growth conditions and are prone to virus contamination. Furthermore, the high cost of maintaining mammalian cell lines and achieving high protein yields present challenges in the market. Furthermore, the potential immunogenicity of recombinant proteins generated in mammalian cells must be carefully assessed. Finally, ethical concerns with the use of mammalian cells in research must be addressed.

Product Segment Insights and Analysis:

Based on the product, the mammalian cell culture market is segmented into consumables and equipment.

Equipment segment contributed the largest market revenue share in 2024. In a well-designed and established mammalian cell culture laboratory, the main cell culture facility is outfitted with a laminar flow hood/biosafety cabinet, a CO2 incubator, an inverted microscope, and other accessory grade small instruments such as temperature-controlled tabletop centrifuges, hemacytometers, or automated cell counter. All these devices are required for mammalian cell culture and can be maintained securely and easily.

On September 2024, Eppendorf has announced the CellXpert CS220, the first CO2 incubator shaker with a built-in 180°C sterilization protocol. This new product is intended to aid mammalian cell culture initiatives, particularly those involving the creation of complicated recombinant proteins, the manufacture of viral vectors, and bioreactor starter cultures. The gadget is also designed to disinfect more easily and quickly by removing internal drive wheels, cover sheets, cables, and heating fins from its stainless-steel chamber. In addition to these advantages, the shaker offers a 40% larger flask capacity and the biggest platform size to footprint ratio offered on the market.

Consumables segment is expected to have the highest growth rate throughout the forecasted period. High demand for mAbs, vaccines, and recombinant proteins necessitates consistent, high-quality consumables like culture media, reagents, and buffers. Expanding applications in gene therapy and regenerative medicine increases the need for specialized consumables optimized for therapeutic-grade cultures. Continuous development of biologics and cell-based assays fuels the need for high-quality consumables.

On October 2024, Croda Pharma has announced the launch of Super Refined Poloxamer 188, a novel bioprocessing solution designed to fulfill the growing demand for biopharmaceutical research. Super Refined Poloxamer 188 has been optimized for mammalian cell culture, with precisely regulated impurity profiles and molecular weight, resulting in superior cell culture performance and batch-to-batch consistency.

Application Segment Insights and Analysis:

Based on the application, the mammalian cell culture market is segmented into diagnostics, biopharmaceutical production, tissue culture & engineering, cell & gene therapy, drug screening and development, toxicity testing, and others.

Biopharmaceutical production segment contributed the largest market revenue share in 2024. Mammalian cell culture is the leading expression system for biologics production due to its ability to perform post-translational modifications, which are critical for drug safety and efficacy. In recent years, the production of biologics using mammalian cell culture has increased significantly due to improvements in volumetric and specific productivities. High productivities and required product characteristics have been attained through the development of high-yielding and stable cell lines, animal-free and productive medium, high-density fed-batch cell culture conditions, and successful scale-up to large production bioreactors.

On July 2023, Lonza has introduced the TheraPRO CHO Media System, a revolutionary cell culture platform that streamlines procedures while improving productivity and protein quality when used with GS-CHO cell lines. This enables pharmaceutical and biotechnology companies producing therapeutic proteins to increase product quality while reducing time-to-market. The two-part production system is chemically defined, free of animal components, and simple to use, making media preparation easier.

Drug screening and development segment is expected to have the highest market growth rate throughout the forecasted period. Human-relevant 3D cell culture models provide an excellent alternative to animal models for medication testing and development. Including more human-relevant models in pre-clinical drug screening efforts would improve efficiency and is crucial for identifying therapeutic candidates who will pass clinical trials and reach the market. The imaging of 3D cell cultures gives useful information about ion gradients, cellular dynamics, gene expression, and other biological and biochemical factors in response to molecular dosage. Integrated automation and machine learning can improve imaging and interpretation efficiency.

On October 2023, Eurofins CDMO Alphora Inc. has announced the introduction of its Biologics program, as part of its strategy to diversify and expand in North America’s contract development and manufacturing market. The project’s first phase, originally scheduled for completion by December 2023, includes a 3,300-square-foot pilot-scale facility dedicated to mammalian cell culture (mAbs) and therapeutic proteins, featuring non-cGMP process development and a production capacity of up to 200L.

End-Use Segment Insights and Analysis:

Based on the end-use, the mammalian cell culture market is segmented into pharmaceutical & biotechnology companies, hospitals and diagnostic laboratories, research & academic institutes, and Contract Research Organizations (CROs).

Pharmaceutical and biotechnology companies segment contributed the largest market revenue share in 2024. Demand for biopharmaceutical products such as vaccines, monoclonal antibodies, and therapeutic proteins is increasing exponentially owing to rapid advancements in healthcare and research sectors. According to the Food and Drug Administration (FDA), as of October 2023, the FDA has granted approval to only 43 biosimilar drugs. Bioreactor manufacturers are working on rapid innovations to increase production mammalian cell-based biologic products.

On December 2024, Boston Institute of Biotechnology, LLC (BIB) and its sister company BiBo Pharma, specializing in large-molecule biologics, stated a major investment to significantly expand production capacity, cementing their leadership in the biologics manufacturing industry. The new facilities will comprise mammalian cell culture production lines with at least four 30,000L, two 15,000L, and one 5,000L (perfusion capable) bioreactors, totaling more than 150,000 liters of operating volume. Furthermore, microbial fermentation production lines will contain three 30,000L, one 10,000L, and two 3,000L fermenters, boosting the working volume by more than 100,000 liters. These expansions will increase BIB’s capacity by nearly 350,000 liters in total volume.

Contract Research Organizations (CROs) segment is expected to have the highest growth rate throughout the forecasted period. Microfluidic devices offer an ideal regulated environment for cell cultivation and drug testing on a wide range of cells, including cancer, hepatocytes, and bacteria. This controlled atmosphere enables for the long-term monitoring of cell cultures. Researchers have leveraged the intrinsic features of microfluidic techniques, such as their ability to handle small sample quantities, monitor processes in real time, and precisely control drug release rates, to overcome the limitations of traditional nanodrug delivery systems (NDDSs). Furthermore, the smooth integration of microfluidic technology with electronic components, robotics, and camera monitoring systems has pushed its use as a superior controlled-release mechanism compared to conventional DDSs.

Geographical Outlook:

Mammalian cell culture market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamics. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different regions and countries.

North America Mammalian Cell Culture:

North America is registered to have highest market revenue share in mammalian cell culture market in 2024. Rising use of mammalian cell culture-based adenovirus vector vaccines and adoption of regenerative medicine are key drivers driving the market revenue growth. According to the American Cancer Society, breast cancer is the most frequent cancer in women in the United States, except for skin cancers. In the United States for 2024, doctors expect to diagnose approximately 310,720 new cases of invasive breast cancer in women and an estimated 56,500 new cases of ductal carcinoma in situ (DCIS), while about 42,250 women are projected to die from breast cancer.

On June 2023, Culture Biosciences and Cytiva are working together to accelerate innovation in upstream bioprocessing by giving customers more access to predictive and resilient scale-up capabilities. As the initial stage in this new relationship, Cytiva’s Bioreactor Scaler currently includes Culture’s 250 mL bioreactor. The bioreactor scaler tool facilitates smooth scaling between development and manufacturing. Scientists can identify scale-up or scale-down process control parameters by entering in their existing process details and cell line characteristics. The tool helps to de-risk scaling activities and ensure product quality.

Asia Pacific Mammalian Cell Culture:

Asia Pacific is registered the fastest growth rate during the forecasted period. This is mainly driven by increasing demand for biopharmaceutical products, investments, and advancements in healthcare infrastructure. On January 2024, AGC Biologics has announced plans to build a new production facility at AGC Inc.’s Yokohama Technical Centre in Japan. The new facility is part of strategic growth strategy to expand high-quality pharmaceutical development and manufacturing services in Asia, allowing to fulfill the global demand for biologics and advanced therapy medical products (ATMPs). The new AGC Biologics facility in Yokohama will provide pre-clinical and commercial services for mammalian-based protein biologics, cell treatments, and messenger RNA (mRNA).

Competition Analysis:

The mammalian cell culture market is characterized by a fragmented structure, with several players competing across various segments and regions. List of major players included in the mammalian cell culture market report are:

• Merck KGaA
• Cytiva
• Thermo Fisher Scientific
• Fujifilm Irvine Scientific
• Novartis AG
• Agilent Technologies, Inc.
• Lonza Group AG
• Corning Inc.
• Horizon Discovery Ltd.
• Promocell GmbH
• HiMedia Laboratories Private Limited
• BD Biosciences
• STEMCELL Technologies
• Cell Culture Company, LLC

Strategic Developments in Mammalian Cell Culture Market:

• In November 2024, Scorpius Holdings, Inc., an integrated contract development and manufacturing company, announced the formation of Scorpius Ventures, a new business unit aimed to provide budding biotech companies with a flexible American onshoring model. Scorpius Ventures eliminates financial obstacles for its partners to onshore biologic production by combining service fees and an equity participation, resulting in a mutually beneficial pathway to expedite biotech developments.
• In July 2024, STEMCELL Technologies has commercialized the CellPore Transfection System, a game-changing new technology with the potential to enhance cell engineering research and the development of novel cell treatments to treat diseases. The CellPore Transfection System is a significant step forward for cell engineering researchers, since it provides a novel technique of cargo delivery into mammalian cells known as mechanoporation.
• In November 2023, Lonza has announced the introduction of their new GS Effex cell line to produce therapeutic antibodies with increased potency. The GS Effex cell line was created to fulfill increasing market demands resulting from the shift to more advanced therapeutic antibodies. GS Effex, derived from Lonza’s flagship GS Xceed cell line, is well-suited to Lonza platforms. Combined with high cell growth and the potential to manufacture therapeutic antibodies with improved potency, the novel cell line offers a solution for therapeutic development from discovery to commercial manufacturing.

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations. The forecast period extends from 2025 to 2032.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights Of The Mammalian Cell Culture Market Report:

The mammalian cell culture market report offers a detailed analysis of market size, including historical revenue (in USD Million) data for 2022-2023 and revenue forecasts for 2025-2032 across the following segments:

• Product Outlook (Revenue, USD Million; 2022-2032)
  • Consumables
    • Media
      • Serum-Free Media
      • Serum-Containing Media
      • Protein-Free Media
      • Specialty Media
    • Reagents
      • Growth Factors
      • Amino Acids
      • Buffers
      • Supplements
      • Others
  • Equipment
    • Bioreactors
      • Single-Use Bioreactors
      • Multi-Use Bioreactors
      • Storage
        • Refrigerators and Freezers
        • Cryostorage Systems
      • Centrifuges
      • Filtration Systems
      • Cell Culture Vessels
      • Others
• Application Outlook (Revenue, USD Million; 2022-2032)
  • Diagnostics
  • Biopharmaceutical Production
    • Monoclonal Antibodies
    • Vaccines Production
    • Others
  • Tissue Culture & Engineering
  • Cell & Gene Therapy
  • Drug Screening and Development
  • Toxicity Testing
  • Others
• End-Use Outlook (Revenue, USD Million; 2022-2032)
  • Pharmaceutical & Biotechnology Companies
  • Hospitals And Diagnostic Laboratories
  • Research & Academic Institutes
  • Contract Research Organizations (CROs)
• Regional Outlook (Revenue, USD Million; 2022-2032)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about the Mammalian Cell Culture market report